Symposia 2010
We are happy to announce ECBS 2010, the Second European Chemical Biology Symposium, taking place on May 20/21 in Prague.
The conference will focus on the topics of protein modifications, molecular chaperons and stem cell biology. It addresses researchers from different scientific areas – chemistry, biology, pharmacology, chemoinformatics, bioinformatics – sharing an interest in the interdisciplinary field of Chemical Biology. The conference will provide ample opportunities to discuss with other experts the ongoing and future research activities.
More information is available at http://www.ecbs2010.eu/.
ChemBioNet-DB Access
Members and Partners of the ChemBioNet are entitled to enter the ChemBioNet-DB. At the moment a database containing structural data and later on screening data from the shared screening collection of the ChemBioNet (about 17.000 compounds from ChemDiv) is provided. Screening data will be provided after permission by the academic screening projects. Structural data of compounds from Chemists of the network (about 4.000 additional compounds) will only be provided after permission by the corresponding spenders.
For access to ChemBioNet-DB contact screening(at)fmp-berlin.de
Actual location is: ChemBioNet Home /
Resource Network Supporting Academic Chemical Biology Research
The ChemBioNet was initiated by biologists and chemists from academia who realized the need for interdisciplinary open access platforms to support research projects for systematic usage of small molecules to explore biological systems.
This initiative wants to provide chemists with bioprofiles for their unique synthetic molecules and biologists developing unique assay systems, with access to high throughput technologies to identify compounds useful for dosage dependent, temporally or locally controlled interference with biological functions. In summary a novel discipline termed Chemical Biology.
Four partner institutes (Helmholtz Centre for Infection Research, the Max-Delbrück-Center for Molecular Medicine, the University of Oslo and the Leibniz-Institut für Molekulare Pharmakologie, FMP) co-financed a shared central compound collection for screening.